Roy A. Whitfield - Jun 14, 2023 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Role
Director
Signature
Mark A. Wilson, Attorney-in-Fact
Stock symbol
NKTR
Transactions as of
Jun 14, 2023
Transactions value $
-$17,100
Form type
4
Date filed
6/15/2023, 06:26 PM
Previous filing
Sep 20, 2022
Next filing
Sep 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTR Common Stock Sale -$17.1K -30K -12.18% $0.57 216K Jun 14, 2023 Direct F1, F2
holding NKTR Common Stock 51.5K Jun 14, 2023 by Whitfield Family 2020 Trust
holding NKTR Common Stock 20K Jun 14, 2023 by Family Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 This transaction was executed in multiple trades at prices ranging from $.57 to $.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.